TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue
Authors:
- Monikongkona BoruahMBMonikongkona Boruah
- Riyaz Ahmad MirRMRiyaz Ahmad Mir
- Sameer RastogiSRSameer Rastogi
- Kapil SikkaKSKapil Sikka
- Shipra AgarwalShipra Agarwal
- 28 August 2026
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 288
Abstract
No abstract availableFunding Information
- Anusandhan National Research Foundation (CRG/2022/002939)
- Indian Council of Medical Research (52/29/2020-Bio/BMS)
This publication has 23 references indexed in Scilit:
- Unravelling the Reasons Behind Limited Response to Anti-PD Therapy in ATC: A Comprehensive Evaluation of Tumor-Infiltrating Immune Cells and CheckpointsEndocrine Pathology, 2024
- The role of Tim-3 blockade in the tumor immune microenvironment beyond T cellsPharmacological Research, 2024
- TIM-3 as a promising target for cancer immunotherapy in a wide range of tumorsCancer Immunology, Immunotherapy, 2023
- ENO1 and CancerMolecular Therapy-Oncolytics, 2022
- PD-L1 as a biomarker of response to immune-checkpoint inhibitorsNature Reviews Clinical Oncology, 2021
- The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancerNature Genetics, 2021
- E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell MigrationScientific Reports, 2019
- Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancerInternational Immunopharmacology, 2018
- Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral toleranceNature Immunology, 2003
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002